SCHEMBL16865692

SCHEMBL16865692

O=S1(=O)CCN(CN2CCCOC2)CO1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ADRA2B P18089 1/20 0.32
HRH1 P35367 1/20 0.32
DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16868385 0.85 ADRA2B (0.40) ADRA2BHRH1DRD3
SCHEMBL6330683 0.79 PDK1 (0.32)
SCHEMBL16868386 0.71 ADRA2B (0.70) ADRA2BHRH1DRD3
SCHEMBL3380412 0.65 USP2 (0.40)
SCHEMBL11352325 0.63
SCHEMBL24801781 0.62
SCHEMBL40427 0.62
SCHEMBL22081189 0.61
SCHEMBL16401532 0.61
SCHEMBL14119200 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159477-A1 PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS GEISTLICH PHARMA AG (CH) 2023-05-25 US disclosed
US-9844555-B2 Oxathiazine derivatives as antibacterial and anticancer agents GEISTLICH PHARMA AG (CH) 2017-12-19 US disclosed
US-20170196876-A1 OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS GEISTLICH PHARMA AG (CH) 2017-07-13 US disclosed
US-9624187-B2 Oxathiazine derivatives as antibacterial and anticancer agents GEISTLICH PHARMA AG (CH) 2017-04-18 US disclosed
US-20160159759-A1 OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS GEISTLICH PHARMA AG (CH) 2016-06-09 US disclosed
US-9241943-B2 Oxathiazine derivatives as antibacterial and anticancer agents GEISTLICH PHARMA AG (CH) 2016-01-26 US disclosed
US-20150182534-A1 OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS GEISTLICH PHARMA AG (CH) 2015-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150182534-A1 OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS OXA1L, TOP2A, HELZ ADRA2B 4731/4885HRH1 2635/4885DRD3 2953/4885
US-20230159477-A1 PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS OXA1L, MAPT, OTC ADRA2B 4370/4885HRH1 1706/4885DRD3 4055/4885
US-20170196876-A1 OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS TOP2A, OXA1L, TOP1 ADRA2B 4660/4885HRH1 2759/4885DRD3 2786/4885
US-20160159759-A1 OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS TOP2A, OXA1L, TOP1 ADRA2B 4660/4885HRH1 2759/4885DRD3 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.